External Validation of the Prostate Biopsy Collaborative Group Risk Calculator and the Rotterdam Prostate Cancer Risk Calculator in a Swedish Population-based Screening Cohort.

ABSTRACT:

Background

External validation of risk calculators (RCs) is necessary to determine their clinical applicability beyond the setting in which these were developed.

Objective

To assess the performance of the Rotterdam Prostate Cancer RC (RPCRC) and the Prostate Biopsy Collaborative Group RC (PBCG-RC).

Design setting and participants

We used data from the prospective, population-based STHLM3 screening study, performed in 2012-2015. Participants with prostate-specific antigen ≥3 ng/ml who underwent systematic prostate biopsies were included.

Outcome measurements and statistical analysis

Probabilities for clinically significant prostate cancer (csPCa), defined as International Society of Urological Pathology grade ≥2, were calculated for each participant. External va

SUBMITTER: Chandra Engel J 

PROVIDER: S-EPMC9257644 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature